Proprotein convertase subtilisin/Kexin type 9 (PCSK9) affects LDL receptor degradation and decreases the clearance of circulating LDL particles, which is crucial in cholesterol metabolism. PCSK9 is predominantly generated by hepatocytes, with additional sources including the intestines and kidneys. PCSK9 reduces LDLR in hepatocytes by increasing their metabolism and eventual death, preventing the receptors from being broken down and allowing them to continue to lower blood cholesterol.
PCSK9 inhibitors indications include patients with familial hypercholesterolemia who are resistant to statins or have increased LDL-C levels while being on maximally tolerated statin...
